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Introduction {#sec1}
============

TNF functions as a master regulator of the cytokine network that coordinates defense of homeostasis by controlling inflammation, cell proliferation, differentiation, survival, and death ([@bib1]). Ubiquitylation has emerged as a crucial mediator of signal transduction in inflammation, stress responses, and defense of homeostasis ([@bib6]). The formation of atypical ubiquitin (Ub) chains produce robust signaling "hubs" that are recognized by specialized Ub-binding proteins ([@bib16]), which subsequently coordinate tissue repair and adaptation to tissue stress. The signaling pathways emanating from TNF receptor-1 (TNF-R1) represent some of the best models to study the role of Ub in the regulation of homeostasis. In mammals, binding of TNF to TNF-R1 triggers either pro-survival/inflammatory or pro-death signaling pathways ([@bib41]). TNF regulates tissue homeostasis by orchestrating three distinct signals: (1) the activation of NF-κB-dependent and MAPK/JNK-dependent transcriptional programs, (2) induction of caspase-8-dependent apoptosis, and (3) stimulation of receptor interacting protein kinase (RIPK)-mediated necrosis (necroptosis) ([@bib5]).

Binding of TNF to TNF-R1 results in the sequential formation of two signaling complexes ([@bib40]). The rapidly forming complex-I is assembled at the receptor's cytoplasmic tail and consists of the adaptor TRADD, RIPK1, TRAF2, cIAP1, and cIAP2. Within this complex, RIPK1 and other proteins are rapidly conjugated with Ub chains of various types. Using Jurkat, L929 cells, and mouse embryonic fibroblasts (MEFs), it was established that ubiquitylation of RIPK1 at K377 is indispensable for TNF-induced activation of NF-κB ([@bib10], [@bib13], [@bib36], [@bib44]). Since then, many additional studies have refined this viewpoint, demonstrating that the requirement of RIPK1 for NF-κB activation is cell type dependent ([@bib4], [@bib33], [@bib43]). Together with LUBAC (linear Ub chain assembly complex; [@bib35]), complex-I signals inflammation and cell survival through TAK1 and IκB kinase (IKK)-dependent activation of NF-κB, which drives production of cytokines as well as pro-survival genes such as *cFlip*.

Through a process still ill defined, complex-I dissociates from the receptor, and RIPK1 together with TRADD associates with the adaptor protein FADD and pro-caspase-8 (casp-8) to form complex-II ([@bib24]). The formation and activity of this signaling platform, which has the potential to initiate apoptosis or necroptosis, is tightly regulated by anti-apoptotic proteins such as cFLIP ([@bib25], [@bib30]). In addition, NEMO and TAK1 also act as regulators of TNF-induced cell death, partly independent of their role in NF-κB activation ([@bib3], [@bib28]). The molecular mechanism underpinning the suppression of TNF-mediated complex-II formation is still poorly characterized. The current dogma dictates that ubiquitylation of RIPK1 mediates activation of NF-κB, cell survival and tissue repair, and its deubiquitylation, by de-ubiquitylating enzymes (DUBs) such as CYLD, enhances complex-II formation and caspase-8-mediated apoptosis or necroptosis ([@bib40]). It is believed that the Ub chains conjugated to RIPK1 by cIAP1/2 and LUBAC in complex-I constitute the decisive factor preventing RIPK1 from forming complex-II and limiting its killing potential ([@bib2], [@bib11], [@bib14]). However, this was recently challenged by the observations that formation of complex-II also occurs under conditions where cIAPs and LUBAC are fully functional and following inhibition of TAK1 as well as loss of NEMO ([@bib7], [@bib18], [@bib28], [@bib27], [@bib30]). Under such conditions, complex-II assembles despite RIPK1 ubiquitylation in complex-I. We and others have also recently identified MK2 as an additional checkpoint that regulates RIPK1 entry into complex-II. MK2 phosphorylates RIPK1 at Ser320 and Ser335 upon TNF stimulation to limit cell death downstream of TNF-R1 ([@bib9], [@bib17], [@bib23]).

Because an inflammatory microenvironment can dictate the aggressiveness of certain tumors, and influence the response to therapy, a better understanding of the complex relationship between cell death and inflammation is critical. This is an important issue because its resolution, and putative therapeutic intervention, would allow the diversion of cancer-related inflammation into activation of cell death. Here, we report that Mind Bomb E3 Ub ligases contribute to the regulation of TNF-induced cell death by inactivating RIPK1 via inhibitory ubiquitylation.

Results {#sec2}
=======

Identification of MIB2 as a RIPK1-Binding Protein {#sec2.1}
-------------------------------------------------

To elucidate what determines whether an inflammatory signal instructs either an innate immune response or triggers cell death, we undertook a proteomic-based approach using components of the TNF-R signaling complex (TNF-RSC) as affinity reagents. Proteins of the TNF-RSC were fused to 2x-HA tags and expressed in Flp-In T-REx-HEK293 cells that allow single-copy insertion of these components under the control of doxycycline (Dox). HA-tagged proteins were purified and the presence of co-purified proteins was determined via mass spectrometry. In addition to known constituents of the native TNF-RSC, we identified the RING-type Ub-E3 ligase Mind Bomb-2 (MIB2) as a RIPK1-interacting protein ([Figure 1](#fig1){ref-type="fig"}A). Notably, MIB2 consistently co-purified with RIPK1 in six independent mass spectrometric experiments. We next verified the interaction of MIB2 with RIPK1 via co-immuno-precipitation and demonstrated that MIB2 readily interacted with RIPK1 ([Figure 1](#fig1){ref-type="fig"}B). MIB1, which shares 42% sequence homology with MIB2, also associated with RIPK1 under these conditions.Figure 1Identification of MIB2 as a Novel Component of TNF Receptor Complex-I(A) Schematic representation of the RIPK1-bound target proteins that were identified by mass spectrometry. The table specifies the sum of the spectral counts across six independent immuno-precipitations for each target protein with a minimum SAINT score probability of 0.86.(B) HA-GFP, HA-MIB1, or HA-MIB2 was co-expressed with untagged RIPK1 in 293T cells. HA-immuno-precipitation was performed and RIPK1 interaction was assessed via western blot.(C--E) TNF-induced complex-I immuno-precipitation. MDA-MB-231 cells (C) or HT1080 cells (D) or WT 786-0 or *RIPK1* knockout (KO) 786-0 cells (E) were treated with FLAG-hTNF (0.8 μg/mL) for the indicated time points, followed by FLAG immuno-precipitation and western blot analysis.(F and G) Western blot analysis of MDA-MB-231 cells (F) or 786-O cells (G) either left untreated or treated with FLAG-hTNF (0.8 μg/mL) for the indicated time points followed by MIB2 immuno-precipitation.

MIB2 Is a Constituent of the Native TNF-RSC {#sec2.2}
-------------------------------------------

Consistent with the notion that MIB2 is part of complex-I, and in agreement with a recent mass spectrometry study ([@bib39]), we found that endogenous MIB2 was readily recruited to the TNF-RSC in a ligand- and time-dependent manner in a range of cell types, including MDA-MB-231, HT1080, and 786-0 ([Figures 1](#fig1){ref-type="fig"}C--1E). MIB2 recruitment was mainly RIPK1 dependent ([Figure 1](#fig1){ref-type="fig"}E) and occurred in the same dynamic manner as described for other components of complex-I ([@bib11], [@bib14], [@bib24]), peaking at 15 min. Reciprocal immuno-precipitation of endogenous MIB2, using MIB2-specific antibodies, likewise co-purified ubiquitylated RIPK1 and other components of complex-I such as TRADD, TNF-R1, and SHARPIN in a TNF- and time-dependent manner in multiple cell types ([Figures 1](#fig1){ref-type="fig"}F and 1G). This demonstrates that MIB2 is recruited to the initial complex-I that forms directly upon TNF stimulation. Although MIB2 is recruited to complex-I, our data indicated that in the cell lines tested, MIB2 had no role in TNF-induced activation of NF-κB, induction of NF-κB target genes such as A20, and the production of cytokines ([Figures S1](#mmc1){ref-type="supplementary-material"}A--S1G).

MIB2 Protects Cells from TNF-Induced and RIPK1-Dependent Cell Death {#sec2.3}
-------------------------------------------------------------------

Given that MIB2 did not modulate TNF-induced activation of NF-κB in the cell lines tested, we explored the role of this E3 ligase in regulating TNF-induced and RIPK1-dependent cell death. We tested a range of different cell lines that exhibit diverse sensitivities to TNF-induced cell death ([Figures S2](#mmc1){ref-type="supplementary-material"}A--S2C) ([@bib34], [@bib38]). Specifically, we tested two paradigms of TNF-induced and RIPK1-dependent cell death, one that relies on the inhibition of TAK1 and one that occurs upon inactivation of IAPs with SMAC mimetic (SM) compounds. Although many cells are sensitive to TNF in the presence of the TAK1 kinase inhibitor 5Z-7-oxozeaenol (hereafter referred to as TAK1i), we focused our attention on a cell line that is largely resistant to this treatment combination, namely, the renal cell adenocarcinoma 786-0. Intriguingly, depletion of *MIB2*, but not *MIB1*, dramatically sensitized 786-0 cells to treatment with TNF in the presence of TAK1i, in both short-term cell death experiments and long-term clonogenic survival assays ([Figures 2](#fig2){ref-type="fig"}A--2C and [S2](#mmc1){ref-type="supplementary-material"}D). Cell death under these conditions was entirely RIPK1 and caspase-8 dependent, as co-depletion of *MIB2* and *RIPK1* or *CASPASE-8* protected cells from the cytotoxic effects of TNF/TAK1i, and treatment with z-VAD-FMK completely suppressed cell death, corroborating the notion that these cells die by apoptosis ([Figures 2](#fig2){ref-type="fig"}B and [S2](#mmc1){ref-type="supplementary-material"}D). In agreement with MIB2 limiting RIPK1- and caspase-8-dependent apoptosis, formation of complex-II was also enhanced upon *MIB2* knockdown ([Figure 2](#fig2){ref-type="fig"}D, top, compare lane 9 with lane 10). *MIB2* depletion also sensitized cells under conditions in which expression of NF-κB target genes were blocked by expressing a dominant-negative form of IκB (Super-Repressor; IκB^SR^) and to a lesser extent upon treatment with cycloheximide (CHX) ([Figures S2](#mmc1){ref-type="supplementary-material"}E and S2F). Moreover, CRISPR/Cas9-mediated deletion of *MIB1* and *MIB2* also sensitized the triple-negative breast cancer cell line MDA-MB-231 to TNF/TAK1i in a RIPK1-dependent manner ([Figure 2](#fig2){ref-type="fig"}E).Figure 2Depletion of MIB2 Sensitizes Cells to TNF-Induced and RIPK1-Dependent Cell Death(A) FACS analysis of PI-positive 786-0 cells subjected to siRNA knockdown of *MIB2*. After siRNA knockdown, cells were treated with the indicated agents for 48 hr. Error bars represent SD.(B) FACS analysis of PI-positive 786-0 cells subjected to siRNA knockdown of indicated genes. After siRNA knockdown, cells were treated with the indicated agents for 48 hr. Error bars represent SD.(C) Clonogenic growth assay of 786-0 cells subjected to siRNA knockdown of indicated genes. 40 hr post-siRNA, 1,000 cells were re-plated, treated with TNF/TAK1i, and left in treated medium to form colonies. Error bars represent SEM. Western blot analysis of 786-0 cells subjected to *MIB1*, *MIB2*, or *MIB1*/*2* knockdown for 40 hr.(D) Immuno-precipitation of complex-II following TNF stimulation. Cells were pre-treated with TAK1i and zVAD for 1 hr (zVAD and TAK1i also added to 0 hr) followed by treatment with FLAG-hTNF (0.8 μg/mL) for the indicated time points. Caspase-8 immuno-precipitation was performed followed by western blot analysis. Quantification of RIPK1 bound to caspase-8 is shown.(E) FACS analysis of PI-positive *MIB1/2* DKO MDA-MB-231 cells subjected to siRNA knockdown of RIPK1 followed by treatment with TNF (10 ng/mL) or TAK1i (1 μM) alone or in combination for 16 hr. Error bars represent SD.(F) Western blot analysis of activated caspase-8 (P41/43 cleavage product) following siRNA-mediated knockdown of *CTRL*, *RIPK1*, or *MIB2* in HT1080 cells and treatment with TNF/SM for 3 hr.(G) FACS analysis of PI/AnnexinV-positive HT1080 cells subjected to siRNA knockdown of the indicated genes followed by treatment with TNF (10 ng/mL) or SM (100 nM) alone or in combination for 6 hr. Error bars represent SEM.(H) FACS analysis of PI-positive *MIB1/2* DKO or *RIPK1* KO MDA-MB-231 cells treated with SM (100 nM) for 16 hr. Error bars represent SD.(I) FACS analysis of PI-positive 786-0 cells treated with TNF (10 ng/mL) or SM (100 nM) or in combination for 48 hr. Error bars represent SD.(J) MTT cell viability assay of MDA-MB-231 cells subjected to siRNA-mediated knockdown of *MIB2*. After siRNA-mediated knockdown, cells were treated with SM (100 nM) or LPS (10 μg/mL) alone or in combination for 3 hr. Error bars represent SD.(K) Western blot analysis of activated caspase-8 (P41/43 cleavage product) following siRNA-mediated knockdown of *CTRL*, *RIPK1*, or *MIB2* in MDA-MB-231 cells and treatment with LPS/SM for 4.5 hr.(L) TNF-induced complex-II immuno-precipitation. MDA-MB-231 cells were treated with the indicated agents for 4 hr. Caspase-8 immuno-precipitation was performed followed by western blot analysis. An asterisk indicates cross reactive bands.

SM compounds block IAP proteins and trigger cytokine-dependent apoptosis in cancer cells. However, only a subset of cancer cells appears to be sensitive to SM treatment, and even sensitive cells can develop resistance. We therefore established the role of MIB proteins in modulating the therapeutic potential of SM compounds. Intriguingly, RNAi-mediated depletion or CRISPR/Cas9-mediated deletion of *MIB2* significantly enhanced activation of caspase-8 and the sensitivity of cells to TNF-induced cell death in the presence of SM in multiple cell types ([Figures 2](#fig2){ref-type="fig"}F--2L). Although RNAi-mediated knockdown of *MIB2* exacerbated the cytotoxic effects of TNF/SM, depletion of *MIB2* was somewhat sufficient to sensitize cells to TNF alone ([Figures 2](#fig2){ref-type="fig"}G and 2I). Interestingly, inhibiting the kinase activity of RIPK1 partially protected HT1080 and 786-0 cells from TNF-mediated cell death upon *MIB2* depletion ([Figures S2](#mmc1){ref-type="supplementary-material"}G and S2H). Although the kinase activity of RIPK1 contributes to apoptosis in these cells, RIPK1's scaffolding function seemed to play the predominant role as depletion or genetic deletion of RIPK1 blocks cell death in these cells ([Figures 2](#fig2){ref-type="fig"}B, 2E, 2F, 2H, 2K, [S2](#mmc1){ref-type="supplementary-material"}K, and S2L). Together, our data suggest that MIBs and IAPs both suppress TNF-dependent and RIPK1-mediated cell death.

Depletion of *MIB2* sensitized cells not only to exogenous TNF but also to autocrine and paracrine TNF, produced in response to treatment with lipopolysaccharide (LPS) that activates TLR4 and drives TLR4-mediated and NF-κB-dependent production of TNF ([Figure 2](#fig2){ref-type="fig"}K). Consistent with an increase in caspase activity (data not shown), we found that activation/cleavage of caspase-8 was enhanced upon knockdown of *MIB2* under these conditions ([Figures 2](#fig2){ref-type="fig"}J and 2K). Additionally, we found that MIB2 co-purified with complex-II ([Figure 2](#fig2){ref-type="fig"}L).

Some cells, such as the rhabdomyosarcoma cell line Kym1, were exclusively reliant on MIB2, as mere knockdown of *MIB2*, using two independent small interfering RNA (siRNA) oligos, induced cell death and loss of clonogenic growth potential ([Figures S2](#mmc1){ref-type="supplementary-material"}I and S2J). Depletion of *MIB2* resulted in RIPK1-mediated formation of complex-II and activation of caspase-8 ([Figures S2](#mmc1){ref-type="supplementary-material"}K and S2L). Genetic deletion of TNF-R1 almost completely abrogated the sensitivity of Kym1 cells to depletion of *MIB2* ([Figure S2](#mmc1){ref-type="supplementary-material"}M). Together, these data indicate that MIB2 protects Kym1 cells from the cytotoxic potential of RIPK1.

To address the role of MIB2 in regulating necroptosis, we used murine SWISS-3T3 cells that can die by apoptosis or necroptosis. Of note, all other cell lines used in our study do not express detectable levels of RIPK3 and hence are refractory to necroptosis triggers. Although depletion of *Mib2* sensitized SWISS-3T3 cells to caspase-mediated and RIPK1 kinase-dependent apoptosis upon treatment with TNF/SM, knockdown of *Mib2* had no effect on necroptosis induced by TNF/SM/zVAD ([Figures S2](#mmc1){ref-type="supplementary-material"}N and S2O). This suggests that at least in SWISS-3T3 cells, MIB2 selectively regulates apoptosis. It is important to note that in these cells, TNF/SM-mediated activation of caspases requires RIPK1 kinase activity. This is evident, as co-treatment with a selective RIPK1 kinase inhibitor blocks caspase activation upon TNF/SM treatment.

MIB2 Binds the Linker Region of Oligomeric RIPK1 {#sec2.4}
------------------------------------------------

Our data are consistent with the notion that MIB2 is a component of the TNF-RSC that contributes to the regulation of TNF-induced cell death. To further characterize the interaction of MIB2 with RIPK1, we generated a panel of deletion constructs for MIB2 ([Figure 3](#fig3){ref-type="fig"}A). We found that the N-terminal MZM region of MIB2 was necessary and sufficient for the interaction of MIB2 with RIPK1 ([Figure 3](#fig3){ref-type="fig"}B) and that deletion of the MZM region of MIB2 ([Figure 3](#fig3){ref-type="fig"}B), or mutation of the coordinating cysteine residue of the ZZ fold within the MZM region of MIB2 ([Figure 3](#fig3){ref-type="fig"}C), abrogated the interaction with RIPK1. We next generated deletion constructs for RIPK1 and tested their ability to bind to MIB2's MZM domain ([Figure 3](#fig3){ref-type="fig"}D). Of note, RIPK1 oligomerization is mediated by either the RHIM or DD domain. Deletion of both these oligomerization domains is required to interfere with RIPK1 homo-oligomerization ([Figures S3](#mmc1){ref-type="supplementary-material"}A--S3F). We found that combined deletion of RIPK1's oligomerization surfaces (RHIM domain and DD, 1-510) abrogated the interaction of MIB2 with RIPK1 ([Figure 3](#fig3){ref-type="fig"}E). Deletion of either the DD domain (1-581) on its own or removal of the RHIM in isolation (ΔRHIM) had no effect on the binding ([Figures 3](#fig3){ref-type="fig"}E and 3F). Although MIB2 did not bind to the kinase domain, it appeared to interact with the linker region of oligomerized RIPK1. Consistently, deletion of the linker region of RIPK1 abrogated MIB2 association ([Figures 3](#fig3){ref-type="fig"}F and [S3](#mmc1){ref-type="supplementary-material"}D). Recombinant MIB2 and RIPK1 also bound to each other under *in vitro* conditions, indicating that this interaction is direct ([Figures 3](#fig3){ref-type="fig"}G and [S3](#mmc1){ref-type="supplementary-material"}G). Under these conditions, *in vitro* translated RIPK1 oligomerized and was active (auto-phosphorylated at S166) ([Figures S3](#mmc1){ref-type="supplementary-material"}H--S3J). Furthermore, we found that *in vitro* translated MIB2 was capable of purifying RIPK1 from cellular extract, particularly following treatment with TNF/SM ([Figure 3](#fig3){ref-type="fig"}H). Taken together, our data suggest that MIB2 interacts with the linker region of oligomerized RIPK1 ([Figure 3](#fig3){ref-type="fig"}I).Figure 3MZM Domain of MIB2 Is Required for Binding to Oligomeric RIPK1(A) Domain organization of MIB2. The MZM, REP, ANK, and RING regions of the protein are indicated. The numbers depict the position of the amino acid of the indicated deletion constructs used.(B) HA-MIB2 deletion constructs were co-expressed with untagged RIPK1 in 293T cells. HA-immuno-precipitation was performed and RIPK1 interaction was assessed via western blot.(C) HA-vector control, HA-MIB2^WT^, or HA-MIB2^ZZ^ (carrying a single point mutation in the ZZ-domain) was co-expressed with untagged RIPK1 in 293T cells. HA-immuno-precipitation was performed, and RIPK1 interaction was assessed via western blot.(D) Schematic representation of RIPK1 constructs used in the binding studies.(E and F) HA-RIPK1 deletion constructs (E) or HA-RIPK1ΔRHIM (F) were co-expressed with FLAG-MIB2 MZM domain in 293T cells. HA-immuno-precipitation was performed and interaction with MIB2 MZM was assessed via western blot.(G) *In vitro* binding assay with recombinant MIB2 and *in vitro* translated RIPK1.(H) Binding assay with MIB2 (*in vitro* translated) and RIPK1 (from cellular extract). MDA-MB-231 cells were left untreated or treated with TNF/SM/zVAD-fmk for 4 hr and lysates were incubated with *in vitro* translated FLAG-MIB2.(I) Schematic representation of the interaction between MIB2 and oligomerized RIPK1.

MIB2 Prevents RIPK1-Induced Death in a RING- and Binding-Dependent Manner {#sec2.5}
-------------------------------------------------------------------------

Although knockdown or genetic deletion of *MIB2* sensitized cells to caspase-8-mediated cell death, reconstitution with wild-type MIB2 suppressed the cytotoxic effects of TNF, as measured by caspase-8 maturation, generation of caspase activity (DEVDase assay), PARP cleavage, formation of complex-II, and viability assays ([Figures 4](#fig4){ref-type="fig"}A--4F). Reconstitution with MIB2^ZZ^, which carries a mutation in the ZZ domain required for RIPK1 binding ([Figures 4](#fig4){ref-type="fig"}B, 4C, and 4E), failed to suppress TNF-induced caspase activation and cell death. Importantly, MIB2 with an amino acid substitution of the second-last Phe residue (MIB2^F\ \>\ A^) that abrogates its E3 ligase activity likewise failed to suppress TNF-induced cell death. Absence or mutational inactivation of MIB2 resulted in enhanced complex-II formation, caspase-8 activation, and cell death. Hence, physical association between MIB2 and RIPK1 is necessary but not sufficient to regulate RIPK1. This is evident because MIB2 RING finger mutants can still bind to RIPK1 ([Figure 3](#fig3){ref-type="fig"}B) but fail to regulate RIPK1-mediated activation of caspase-8 and cell death ([Figures 4](#fig4){ref-type="fig"}A--4F). These data suggest that after binding, MIB2 inhibits RIPK1 through a mechanism that is dependent on the E3 ligase activity of MIB2.Figure 4MIB2 Protects Cells from TNF-Induced and RIPK1-Dependent Cell Death, in a RING- and RIPK1-Binding-Dependent Manner(A) Schematic diagram of the reconstitution system using MDA-MB-231 cells. Doxycycline treatment induces simultaneous knockdown of endogenous MIB2 and expression of shRNA resistant wild-type *MIB2*, *MIB2*^*ZZ*^, *MIB2*^*F\ \>\ A*^, or *RFP*. TRE, tetracycline response element; UBC, ubiquitin promoter; rtTA3, reverse Tet transactivator.(B and C) MTT cell viability assay of the indicated stable cells following induction of the target genes with doxycycline (500 ng/mL) for 64 hr and treatment with TNF (10 ng/mL) + SM (100 nM) for 3 hr (B) or with LPS (10 μg/mL) + SM (100 nM) for 5 hr (C). Error bars represent SD.(D) Western blot analysis of activated caspase-8 (P41/43 cleavage product) using stable cells described in (A). Cells were induced for 64 hr with 500 ng/mL of doxycycline and treated ± LPS (10 μg/mL) + SM (100 nM) for 5 hr.(E) DEVDase activity analysis using stable cells described in (A). Cells were induced for 64 hr with 500 ng/mL of doxycycline and treated with LPS (10 μg/mL) or SM (100 nM) alone or in combination for 3 hr. Error bars represent SD.(F) TNF-induced complex-II immuno-precipitation. Stable cells described in (A) were induced with doxycycline for 64 hr and treated with the indicated agents for 4 hr. Caspase-8 immuno-precipitation was performed followed by western blot analysis.

MIB2 Ubiquitylates RIPK1 upon TNF Stimulation Independently of cIAPs {#sec2.6}
--------------------------------------------------------------------

Our data indicate that MIB2 is recruited to complex-I and suppresses the cytotoxic effect of RIPK1 in a RING finger-dependent manner. Consistent with the notion that RIPK1 is a physiological substrate of MIB2, we found that depletion or genetic deletion of *MIB2* resulted in a reduction in ubiquitylation of RIPK1 in complex-I in both MDA-MB-231 and 786-0 cells ([Figures 5](#fig5){ref-type="fig"}A and [S4](#mmc1){ref-type="supplementary-material"}A). Although RNAi-mediated depletion or genetic deletion of *MIB2* resulted in reduced levels of ubiquitylated RIPK1 in complex-I, this had no apparent effect on the kinetics of the recruitment of other components of the TNF-RSC ([Figure S4](#mmc1){ref-type="supplementary-material"}A) and did not affect TNF-induced activation of NF-κB ([Figures 5](#fig5){ref-type="fig"}B and [S4](#mmc1){ref-type="supplementary-material"}B). Of note, MDA-MB-231, 786-0, and Kym-1 cells do not rely on RIPK1 for NF-κB activation and cytokine production ([Figures 5](#fig5){ref-type="fig"}B, 5C, [S4](#mmc1){ref-type="supplementary-material"}B, and S4D), corroborating the notion that the requirement of RIPK1 for NF-κB activation is cell type dependent ([@bib4], [@bib33], [@bib43]). Moreover, RIPK1 is not required for ERK, p38, and JNK activation downstream of TNF in 786-0 cells ([Figure S4](#mmc1){ref-type="supplementary-material"}C). Although RIPK1 is required for NF-κB activation in Jurkat cells ([Figure S4](#mmc1){ref-type="supplementary-material"}E; [@bib10]), we were unable to investigate the role of MIB2 in RIPK1-mediated signaling downstream of TNF in Jurkat cells, because these cells do not survive long-term loss of MIB2 and are not sufficiently transfectable with siRNA oligos (data not shown). Following stimulation with TNF, MIB2 ubiquitylated RIPK1 in complex-I in a manner that was independent of IAPs. This is evident as the polyUb-smearing pattern of RIPK1 reproducibly increased in an IAP-independent yet MIB2-, TNF-, and time-dependent manner ([Figures 5](#fig5){ref-type="fig"}D--5F). Using the reconstitution system described in [Figure 4](#fig4){ref-type="fig"}A, we examined the requirement of the RING finger of MIB2 to promote RIPK1 ubiquitylation. Although wild-type MIB2 readily ubiquitylated RIPK1, the E3-Ub-deficient MIB2 mutant MIB2^F\ \>\ A^ failed to ubiquitylate RIPK1 ([Figures 5](#fig5){ref-type="fig"}E and 5F). MIB2 also ubiquitylated RIPK1 with the help of UbcH5a in an *in vitro* ubiquitylation assay ([Figures 5](#fig5){ref-type="fig"}G and [S4](#mmc1){ref-type="supplementary-material"}G). Although MIB1 also ubiquitylated RIPK1, it was somewhat less efficient than MIB2 ([Figure S4](#mmc1){ref-type="supplementary-material"}F).Figure 5MIB2 Ubiquitylates RIPK1 in a TNF-Dependent Manner(A) TNF-induced complex-I immuno-precipitation depicting the ubiquitylation of RIPK1. WT and *MIB1/2* DKO MDA-MB-231 cells were treated with FLAG-TNF (0.8 μg/mL) for the indicated time points, followed by FLAG immuno-precipitation and western blot analysis. Quantification for ubiquitylation is shown at 15 min time point.(B) Comparison of TNF-induced NF-κB activation in parental and *RIPK1* KO MDA-MB-231 cells. Cells were either left untreated or treated with TNF (10 ng/mL) for indicated times and lysates were analyzed by western blotting(C) The presence of cytokines in the culture media of parental and *RIPK1* KO MDA-MB-231 cells was determined by ELISA. Cells were stimulated with TNF for 6 hr. Error bars represent SD.(D) TUBE affinity purification of lysates from WT and *MIB1/2* DKO MDA-MB-231 cells pre-treated with SM (100 nM) for 10 min, followed by TNF (10 ng/mL) for the indicated time points.(E) TUBE affinity purification of lysates from reconstituted MDA-MB-231 cells. Expression of the indicated proteins was induced with doxycycline (500 ng/mL) for 64 hr followed by pre-treatment with SM (100 nM) for 10 min, after which TNF (100 ng/mL) was added for the indicated times. Quantification of ubiquitylated RIPK1 above the dotted line at 15 and 30 min.(F) Western blot analysis of reconstituted MDA-MB-231 cells. Prior treatment, expression of the indicated proteins was induced with doxycycline (500 ng/mL) for 60 hr. Cells were either left untreated or treated with TNF (100 ng/mL) in the presence or absence of SM (100 nM) for 30 min followed by MIB2 immuno-precipitation.(G) *In vitro* ubiquitylation assay using the indicated purified proteins. The presence of ubiquitylated RIPK1 was evaluated by immunoblotting the reaction with an anti-RIPK1 antibody.

MIB2 Conjugates Different Types of Ub Chains to RIPK1 {#sec2.7}
-----------------------------------------------------

To determine the Ub linkage types that are conjugated to RIPK1 by MIBs, we used UbiCRest (Ub chain architecture using Ub chain restriction; [@bib15]) analysis of RIPK1 in complex-I in the presence and absence of *MIB1/2*. Although the overall intensity of the ubiquitylation smearing pattern of RIPK1 was enhanced in the presence of endogenous MIB2 ([Figure 6](#fig6){ref-type="fig"}A), there was no apparent change in the Ub linkage repertoire. Accordingly, incubation with the respective DUBs resulted in a reduction of the Ub smearing pattern, indicating that K11-, K48-, and K63-linkage types were present. This demonstrates that K63-, K48-, and K11-linked chains were present in both *MIB1/2*-proficient as well as *MIB1/2*-deficient cells but are more abundant when MIBs are present. This suggests that endogenous MIBs can conjugate K11-, K48-, and K63-linked Ub chains to RIPK1. Using K-only Ub, we confirmed that MIB2 was indeed capable of conjugating K11-, K48-, and K63-linked polyUb chains to RIPK1 ([Figure 6](#fig6){ref-type="fig"}B).Figure 6MIB2 Ubiquitylates the Linker and the C-Terminal Portion of RIPK1 with Different Types of Linkages(A) UbiCRest analysis of ubiquitylated RIPK1 associated to complex-I. WT and *MIB1/2* DKO MDA-MB-231 cells were treated with FLAG-TNF (0.8 μg/mL) for 10 min, and complex-I was immuno-precipitated using FLAG beads. Beads were aliquoted and treated with the indicated DUBs in parallel reactions for 30 min at 37°C. The ubiquitylation status of RIPK1 was analyzed by western blot.(B) MIB2 can target RIPK1 for ubiquitylation with K11-, K48-, and K63-linked chains. The indicated constructs were co-expressed in HEK293T cells, and lysates were immunoblotted with an anti-RIPK1 antibody.(C) Schematic representation of all ubiquitylation sites of RIPK1 identified by mass spectrometry-based experiments. Each circle indicates an independent experiment. Green marks previously identified residues.(D) Schematic representation of the ubiquitylation sites of RIPK1 that are mediated by MIB2. Fold Ub enrichment of RIPK1 sites in MIB2^WT^ compared with MIB2^F \> A^ is shown.(E) diGly MS/MS spectra of K377 of human RIPK1 (precursor ion 688.0078^3+^, error −0.58 ppm, ion score 21.8). For clarity, only prominent fragment ions are marked.(F) Ubiquitylation of RIPK1 in complex-I. *RIPK1* KO MDA-MB-231 cells reconstituted with either *RIPK1*^*WT*^ or *RIPK1*^*K377R*^ were treated with FLAG-hTNF for the indicated time points, followed by FLAG immune-precipitation and western blot analysis. Quantification for RIPK1 ubiquitylation is shown.(G) Immuno-precipitation of RIPK1 from *RIPK1* KO MDA-MB-231 cells reconstituted with either *RIPK1*^*WT*^ or *RIPK1*^*K377R*^. Cells were treated with FLAG-hTNF for the indicated time points, followed by RIPK1 immuno-precipitation and western blot analysis. Quantification for RIPK1 phosphorylation is shown.

MIB2 Ubiquitylates RIPK1 at Multiple Sites {#sec2.8}
------------------------------------------

To identify the lysine (K) residue(s) of RIPK1 that are ubiquitylated by MIB2, we used a semiquantitative mass spectrometry-based approach. In total, 14 K residues of RIPK1 were found to be modified by Ub ([Figure 6](#fig6){ref-type="fig"}C). These included previously reported K residues (green dots) ([@bib29]) as well as several additional ubiquitylation sites on RIPK1 (yellow) ([Figure 6](#fig6){ref-type="fig"}C). The identified K residues of RIPK1 clustered into three regions: (1) kinase domain, (2) region surrounding K377, and (3) death domain (DD). Of the Ub-modified K residues, only four sites were specifically enriched by MIB2^WT^ versus MIB2^F\ \>\ A^ (K316, K571, K604, and K634) ([Figure 6](#fig6){ref-type="fig"}D). K377 of human RIPK1, previously reported to be crucial for TNF-induced cell death ([@bib10], [@bib21], [@bib28]), was not detected by mass spectrometry, because the tryptic digest generates peptide fragments that are too long for analysis. To address this issue, we conducted targeted mass spectrometry using double digestion with Trypsin and GluC. Although this approach successfully identified K377 of human RIPK1 as being ubiquitylated ([Figure 6](#fig6){ref-type="fig"}E), this approach did not allow accurate quantification of this ubiquitylation event. Whereas MIB2 readily ubiquitylated wild-type RIPK1, mutating K377 to R significantly reduced MIB2-mediated ubiquitylation of RIPK1 ([Figure S5](#mmc1){ref-type="supplementary-material"}A). As expected, the ability of MIB2 to ubiquitylate K377 was critically dependent on MIB2's own RING finger activity, as the E3-deficient MIB2^F\ \>\ A^ mutant failed to ubiquitylate RIPK1 ([Figure S5](#mmc1){ref-type="supplementary-material"}A). Although RIPK1^K377R^ was less ubiquitylated in complex-I ([Figure 6](#fig6){ref-type="fig"}F), this mutant was significantly more auto-phosphorylated at S166 ([Figure 6](#fig6){ref-type="fig"}G). This indicates that ubiquitylation at K377 represses RIPK1's kinase activity. RIPK1^K377R^ interacted with MIB2 as efficiently as RIPK1^WT^, indicating that deregulation of RIPK1^K377R^ was not due to impaired MIB2 binding ([Figure S5](#mmc1){ref-type="supplementary-material"}B).

MIB2-Mediated Ubiquitylation of K377 and K634 Suppresses RIPK1's Cytotoxic Potential {#sec2.9}
------------------------------------------------------------------------------------

Of the identified residues, K604 and K634 are positioned at the interface between two RIPK1 DD (type I and II interfaces) ([Figures 7](#fig7){ref-type="fig"}A--7D). Given their position, ubiquitylation of these residues is predicted to affect RIPK1 self-association. K634 also locates between RIPK1's DD and FADD's DD (type II interface), which is predicted to directly affect the interaction if ubiquitylated. Consistent with the structural prediction, we found that reconstituted RIPK1^K634R^ cells were considerably more sensitive than RIPK1^WT^ cells when challenged with TNF/TAK1i ([Figures 7](#fig7){ref-type="fig"}E, 7F, and [S6](#mmc1){ref-type="supplementary-material"}). RIPK1^K634R^ was as cytotoxic as RIPK1^K377R^, indicating that ubiquitylation of either of these two sites represses the killing potential of RIPK1. Consistent with the notion that MIB2 regulates RIPK1 by targeting multiple K residues, depletion of MIB2 further reduced ubiquitylation of RIPK1^K634R^ and RIPK1^K377R^ ([Figures S7](#mmc1){ref-type="supplementary-material"}A and S7B) and further sensitized RIPK1^K377R^ cells to TNF killing ([Figure 7](#fig7){ref-type="fig"}G). Together, these data indicate that MIB2 antagonizes the lethal effects of TNF by attaching Ub chains to the linker and C-terminal portion of RIPK1, thereby skewing TNF's signaling potential toward pro-survival and pro-inflammation rather than cell death.Figure 7MIB2 Ubiquitylates RIPK1 at Lysines K377 and K634(A--D) A homology model of human RIPK1 death domain (DD) (583--669) was generated by the SWISS-MODEL server. The PIDD DD (PDB: [2OF5](pdb:2OF5){#intref0015}) was used as homology template. RIPK1 DD model was aligned to Fas DD in Fas/FADD complex structure (PDB: [3OQ9](pdb:3OQ9){#intref0020}) (A). Residues K604 (B) and K634 (C) are found at the interface between two RIPK1 DD (type I and II interfaces), which should affect RIPK1 self-association if ubiquitinated. K634 also locates between RIPK1 DD and FADD DD (type II interface) (D), which is predicted to directly affect the interaction if ubiquitylated.(E) DEVDase activity assay of *RIPK1* KO MDA-MDA-MB-231 cells reconstituted with *RFP*, *RIPK1*^*WT*^, *RIPK1*^*K377R*^, or *RIPK1*^*K634R*^ and treated with TNF/TAK1i for 3 hr. Expression of *RFP*, *RIPK1*^*WT*^, *RIPK1*^*K377R*^, or *RIPK*^*K634R*^ was induced with doxycycline for 3 hr. Error bars represent SD.(F) FACS analysis of PI-positive *RIPk1* KO MDA-MB-231 cells reconstituted with either RFP, *RIPK1*^*WT*^, *RIPK1*^*K377R*^, or *RIPK1*^*K634R*^ and treated with TNF/TAK1i for 3 hr. Error bars represent SD.(G) FACS analysis of PI-positive MDA-MB-231 *RIPK1 KO* cells reconstituted with *RIPK1*^*WT*^ or *RIPK1*^*K377R*^ following MIB2 knockdown. Cells were stimulated with TNF/TAK1i for 3 hr. Error bars represent SD.

Discussion {#sec3}
==========

Ub-mediated inactivation of RIPK1 has long been postulated to contribute to the regulation of cytokine-induced cell death ([@bib10], [@bib26], [@bib28]). cIAP- and LUBAC-mediated ubiquitylation of RIPK1 is a decisive factor in limiting the formation of complex-II ([@bib2], [@bib11], [@bib14]). In the absence of either cIAPs or LUBAC or inhibition of the TAK1-IKKβ axis, TNF fails to activate canonical NF-κB effectively, and consequently, the levels of NF-κB target genes that limit complex-II activity, such as cFLIP~L~, are insufficient to prevent caspase-8-mediated cell death. Primarily this occurs via the induction of NF-κB and the upregulation of cFLIP, but recent evidence suggests that TAK1 and IKK can regulate TNF killing independent of their role in NF-κB activation ([@bib3], [@bib8], [@bib28]). In the absence of functional TAK1 and IKK, lethal levels of complex-II assemble despite RIPK1 ubiquitylation in complex-I ([@bib7], [@bib8], [@bib19]). Under these conditions, TNF-mediated RIPK1-dependent apoptosis was shown to rely on the kinase activity of RIPK1 ([@bib7], [@bib42]). Thus, cells regulate TNF-induced cell death through multiple mechanisms.

Here, we have identified MIB2 as an E3 ligase that can regulate TNF killing. We find that it selectively regulates TNF-induced cell death, while it plays no role in NF-κB activation in the systems tested. MIB2 directly binds to RIPK1 and conjugates inhibitory Ub chains to the linker and the C-terminal portion of RIPK1. Although it remains to be determined how ubiquitylation of K377 suppresses RIPK1 kinase activity (auto-phosphorylation), ubiquitylation of K604 and K634 is predicted to affect RIPK1 self-association, as these residues are positioned at the interface between two RIPK1 DDs. Moreover, K634 is located between RIPK1's DD and FADD's DD, which is predicted to directly affect the interaction if ubiquitylated.

Different cells have different sensitivities to modulation of cIAPs and MIB2. Some cells are acutely sensitive to TNF-induced cell death in the absence of cIAPs or MIB2, while others are not. Consistently, while RNAi-mediated knockdown of MIB2 exacerbates the cytotoxic effects of TNF/SM, depletion of MIB2 is sufficient to sensitize certain cells to TNF alone ([Figures 2](#fig2){ref-type="fig"}G and 2I). The efficiency with which TNF/*siMIB2* induces cell death is comparable with that triggered by TNF/SM ([Figures 2](#fig2){ref-type="fig"}G and 2I). As cIAPs not only control TNF killing but also are key mediators of TNF-induced activation of NF-κB and the expression of pro-survival genes ([@bib32]), their role clearly extends beyond simple regulation of RIPK1's cytotoxic potential. In contrast, MIB2 appears to exclusively inhibit RIPK1's killing potential. The notion that MIB2 contributes to the resistance to RIPK1-mediated cell death is also supported by the observation that high levels of MIB2 inhibit cell death triggered by TNF, SM, TNF/SM, or TNF/TAK1i. Because pharmacological inhibitors of IAPs are in clinical testing, our data suggest that targeting the MIB2 Ub ligase might improve the efficacy of SMs for the treatment of cancer. However, it should be noted that resistance to SM treatment can occur in multiple ways. Although levels of MIB2 clearly matter with regard to SM sensitivity, cells can also become resistant to SM by loss of autocrine-TNF, TNF-R1, RIPK1, FADD, caspase-8, and other mechanisms.

The importance of the E3 ligase activity of MIB2 in regulating RIPK1 and TNF-induced cell death, is highlighted by MIB2 variants bearing RING mutations. The ability of MIB2 to protect from the cytotoxic effects of TNF is strictly dependent on MIB2 neutralizing RIPK1 in a binding- and Ub-dependent manner. MIB2 mutations that selectively abrogate binding or ubiquitylation of RIPK1 cause loss of MIB2 function. The ability of MIB2 to bind to RIPK1 depends on activation of TNF-R1. This may be because TNF-mediated clustering of TNF-R1 results in oligomerization of RIPK1, which in turn is essential for MIB2 to bind and ubiquitylate RIPK1. In the absence of TNF-R1 activation, MIB2 does not associate with RIPK1, potentially because HSP90 sequesters RIPK1 in its monomeric, kinase inactive state ([@bib20]). Thus, under resting conditions, RIPK1 seems to reside in an inactive configuration that precludes MIB2 binding. Only when it is recruited to TNF-R1 can it bind tightly to MIB2. In this respect, MIB2 may sense the activity status of RIPK1. This is similar to cIAPs, which also only regulate RIPK1 upon cytokine stimulation ([@bib37], [@bib38]).

The question remains why there is an apparent overlap in the functions of MIB2 and cIAPs. One possible scenario might be that MIB2 and cIAPs target different K residues of RIPK1. It is interesting that MIB2 preferentially ubiquitylates the linker and the C-terminal portion of RIPK1, while other E3 ligases prefer to ubiquitylate the kinase domain ([Figure 6](#fig6){ref-type="fig"}C), albeit TRAF2/cIAPs also reportedly ubiquitylate K377 ([@bib28]), which seems to be a prominent Ub acceptor K. MIB2-mediated ubiquitylation of RIPK1 appears to interfere with RIPK1 oligomerization (DD-DD interactions), while cIAP-dependent RIPK1 ubiquitylation may suppress its kinase activity, which is required for complex-II formation in some cell types ([@bib7], [@bib42]).

Together, our data demonstrate that MIB2 contributes to inhibiting the pro-apoptotic activity of RIPK1. Although MIB2 is clearly not the only E3 ligase that can target RIPK1 for ubiquitylation, it is unique in its ability to selectively limit TNF-induced killing without affecting activation of TAK1, IKK, p38, JNK, and NF-κB in our system. Other E3 ligases in complex-I, such as cIAPs and LUBAC, influence TAK1 and IKK activation. Through ubiquitylation of RIPK1, MIB2 seems to consolidate the ubiquitylation status of RIPK1 in complex-I, thereby suppressing its transition to complex-II. The absence of MIB2 therefore specifically converts the predominant survival signal that originates from TNF-R1 into a death signal, a situation that might be relevant upon viral infection (pattern recognition receptor activation) or engagement of multiple cytokine receptors ([@bib12], [@bib34]).

Experimental Procedures {#sec4}
=======================

Further details and an outline of resources used in this work can be found in [Supplemental Experimental Procedures](#mmc1){ref-type="supplementary-material"}.

Cell Culture {#sec4.1}
------------

HT1080^IkB-SR^, Kym1, HT1080, MDA-MB-231, Jurkat, SWISS-3T3, HEK293T, and Flp-In-REx-HEK293 cells were cultured in DMEM; 786-0 cells were cultured in RPMI-1640 medium. Culture media were supplemented with 10% fetal bovine serum (GIBCO), penicillin, and streptomycin (GIBCO), and all cells were cultured at 37°C with 10% CO~2~ in a humidified incubator.

Generation of CRISPR Cells {#sec4.2}
--------------------------

Guide RNAs (gRNAs) were designed according to the Church lab ([@bib22]) or Zhang lab ([@bib31]). Prior to CRISPR/Cas9 editing, cells were sorted using fluorescence-activated cell sorting (FACS), and single clones were isolated and characterized. Single-cell clones were then transfected with Cas9 and gRNA targeting the gene of interest using Invitrogen reagents. Three days after transfection, cells were FACS-sorted, and single clones were isolated and screened for the deletion of the gene of interest. *MIB2* knockout clones or were further used to generate *MIB1/2* knockout cells. Positive clones were characterized. Guide sequences are available upon request.

Immuno-Precipitation Assays {#sec4.3}
---------------------------

Immuno-precipitation assays were performed as previously described ([@bib17]). For all immuno-precipitation assays cells were treated as indicated and lysed on ice in DISC lysis buffer supplemented with protease inhibitors. Cell lysates were rotated at 4°C for 20 min and then clarified at 4°C at 14,000 rpm for 10 min. Anti-FLAG M2 beads (20 μL) (Sigma), 20 μL of anti-HA beads (Sigma), or 20 μL of protein A/G agarose (Pierce) + MIB2 antibody (Bethyl Laboratories) or RIPK1 BD antibody; 1 μg antibody/mg protein lysate were rotated with cleared protein lysates overnight at 4°C. Washes (4×) in wash buffer (50 mM Tris \[pH 7.5\], 150 mM NaCl, 0.1% Triton X-100, and 5% glycerol) were performed, and samples eluted by boiling in 50 μL 1× SDS loading dye.

Statistics {#sec4.4}
----------

Statistical analysis was performed using GraphPad Prism version 6.0. Unless otherwise specified, data are presented as mean ± SEM. Comparisons were performed using a Student's t test whose values are represented in the figures as ^∗^p \< 0.05, ^∗∗^p \< 0.01, and ^∗∗∗^p \< 0.001.
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